Month: October 2021
Data indicate that gene therapy appears to be effective, particularly in neuroischemic ulcers Excerpt from the Press Release: SAN DIEGO, Oct. 22, 2021 /PRNewswire/ — Helixmith, a gene therapy company based in Seoul, Korea and San Diego, CA, announced today the results of a Phase 3 study for the treatment of diabetic foot ulcers with their novel gene therapy VM202 (Engensis)…
Read More
Scientists at La Jolla Institute for Immunology received $2.6 million as part of a larger effort to develop protective shots against past, present and future coronaviruses. Excerpt from the Press Release: SARS. MERS. COVID-19. Coronaviruses caused all three diseases, and scientists are betting other members of this viral family will cause new outbreaks. But what…
Read More
Excerpt from the Press Release: Agilent Technologies Inc. (NYSE: A) today announced it has received CE-IVD mark approval for the PD-L1 IHC 28-8 pharmDx to guide options for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastroesophageal junction, or esophageal cancers. Gastric (stomach) cancer is the fifth most common cancer and the…
Read More
Second study of evorpacept in patients with myeloid malignancies Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced the first patient has been dosed in the Phase…
Read More
Excerpt from the Press Release: SAN CARLOS, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA] a company focused on developing cellular and cell derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the treatment of the first patient in its Phase III pivotal CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial for patients…
Read More
BEPro is a novel prodrug technology to enhance oral delivery of active nucleotides Excerpt from the Press Release: EMERYVILLE, Calif.–(BUSINESS WIRE)– Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced the signing of a collaboration agreement granting China Resources Double-Crane Pharmaceutical Co., Ltd. (CRDC) exclusive Asia territorial rights to develop a novel investigational oral COVID-19 antiviral therapeutic compound using…
Read More
Designation provides expedited regulatory review of Exo-PDAC, a liquid biopsy assay, built on the company’s Verita™ platform to detect pancreatic ductal adenocarcinoma earlier in high-risk adults Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Biological Dynamics, Inc., a multiomics liquid biopsy company focused on detecting cancers at the earliest stages, today announced that the U.S. Food…
Read More
COVISTIX has received CE mark and marketing authorization from FAMHP (Federal Agency for Medicines and Health Products) that enables Sorrento to sell this device in all territories that accept the Qarad EC-Rep (Belgium) CE Mark for commercialization. Distribution contracts are being negotiated. Excerpt from the Press Release: SAN DIEGO, Oct. 20, 2021 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”)…
Read More
–Conditional modulation of proteins in their functional state opens a new dimension in precision oncology– –IND-enabling studies expected to initiate in 1H 2022 for TEAD program and in 2H 2022 for CDK2 program– Excerpt from the Press Release: CAMBRIDGE, Mass.–(BUSINESS WIRE)–Cedilla Therapeutics, a biotechnology company bringing a new dimension to precision oncology, today revealed its…
Read More
Excerpt from the Press Release: ATLANTA, Oct. 19, 2021 /PRNewswire/ — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson’s disease and related disorders, today announced dosing of the first Parkinson’s patient in its Phase 1b clinical trial of IkT-148009, an Abelson Tyrosine Kinase, or c-Abl, inhibitor…
Read More